Badlaeva Alina, Tregubova Anna, Asaturova Aleksandra, Melli Beatrice, Cusenza Vincenza Ylenia, Palicelli Andrea
1st Pathology Department, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov of the Ministry of Health of Russia, Bldg. 4, Oparina Street, Moscow 117513, Russia.
Molecular Pathology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Cancers (Basel). 2025 Apr 22;17(9):1398. doi: 10.3390/cancers17091398.
: Gestational trophoblastic disease (GTD) is a group of disorders including complete, partial, and invasive/metastatic hydatidiform moles, as well as gestational trophoblastic neoplasia (GTN) (choriocarcinoma; placental site trophoblastic tumor, PSTT; epithelioid trophoblastic tumor, ETT; or mixed forms). These entities are characterized by increased trophoblast proliferation, rarely complicated by hyperthyroidism. : Our systematic literature review (PRISMA guidelines; PubMed, Web of Science, and Scopus databases) searched for histologically confirmed cases of GTN associated with clinical or subclinical hyperthyroidism. We described the clinical-pathologic features and the pathways of hyperthyroidism in GTD. : We identified just 32 choriocarcinomas and one PSTT; other non-histologically confirmed cases could have been identified, as some patients received a clinical diagnosis based on serum human chorionic gonadotropin (hCG) levels and imagining data and were treated accordingly. As regards choriocarcinomas, patients' age range was 15-45 (mean 27) years. Metastases involved the lungs (53%), brain (25%), and liver (19%) (less frequently, the kidneys, spleen, ovaries, vagina, pelvis/abdomen, or thyroid). The time to recurrence range was 1-36 (mean 12) months. On follow-up, 10 patients (32%) were alive with disease and 6 (19%) showed no evidence of disease, while most of the women (15 cases, 48%) died of disease. The hCG level range was 10,000-3,058,000,000 (mean 128,957,613) IU/L. At least some symptoms and/or signs of hyperthyroidism were evident with variable intensity in most cases and significantly improved within 2-3 weeks after treatment. : Increased trophoblast proliferation could stimulate thyroid function via increasing the half-life of thyroxine-binding globulin. Secondly, increased hCG demonstrates cross-reactivity with the thyroid-stimulating hormone due to similar α-subunits. Moreover, basic isoforms of hCG may facilitate thyrotropic activity.
妊娠滋养细胞疾病(GTD)是一组疾病,包括完全性、部分性和侵袭性/转移性葡萄胎,以及妊娠滋养细胞肿瘤(GTN)(绒毛膜癌;胎盘部位滋养细胞肿瘤,PSTT;上皮样滋养细胞肿瘤,ETT;或混合形式)。这些实体的特征是滋养细胞增殖增加,很少并发甲状腺功能亢进。
我们的系统文献综述(PRISMA指南;PubMed、Web of Science和Scopus数据库)检索了经组织学证实的与临床或亚临床甲状腺功能亢进相关的GTN病例。我们描述了GTD中甲状腺功能亢进的临床病理特征和途径。
我们仅识别出32例绒毛膜癌和1例PSTT;可能还有其他未经组织学证实的病例,因为一些患者是根据血清人绒毛膜促性腺激素(hCG)水平和影像学数据进行临床诊断并相应接受治疗的。对于绒毛膜癌,患者年龄范围为15至45岁(平均27岁)。转移部位包括肺(53%)、脑(25%)和肝(19%)(较少见的有肾、脾、卵巢、阴道、盆腔/腹部或甲状腺)。复发时间范围为1至36个月(平均12个月)。随访时,10例患者(32%)带瘤存活,6例(19%)无疾病证据,而大多数女性(15例,48%)死于疾病。hCG水平范围为10,000至3,058,000,000 IU/L(平均128,957,613 IU/L)。在大多数情况下,至少有一些甲状腺功能亢进的症状和/或体征明显,强度各异,且在治疗后2至3周内显著改善。
滋养细胞增殖增加可通过增加甲状腺素结合球蛋白的半衰期来刺激甲状腺功能。其次,hCG增加由于α亚基相似而与促甲状腺激素表现出交叉反应。此外,hCG的基本异构体可能促进促甲状腺活性。